良性前列腺增生的药物治疗对疗效的影响对比研究

目的研究良性前列腺增生(BPH)患者在治疗过程中同时服用5α-还原酶抑制剂和α1A-肾上腺能受体阻滞剂对疗效的影响。方法选取76位BPH患者随机分配为试验组(38例)和对照组(38例),试验组在接受相同基础治疗的条件下联合服用5α-还原酶抑制剂(依立雄胺)和α1A-肾上腺能受体阻滞剂(多沙唑嗪),对照组只接受一般治疗,通过观察比较3个月后在国际前列腺症状评分、生活质量、前列腺体积、最大尿流率等指标上的差异,来探究药物治疗的疗效。结果与对照组相比,试验组患者在以下3个指标方面有明显改善并有统计学意义:改善自觉症状(P<0.01)、降低最大尿流率(P<0.05)、提高生活质量(P<0.05)。在前列腺体积缩小方面差异无统计学意义。结论同时服用5α-还原酶抑制剂和肾上腺能α1A-受体阻滞剂的药物治疗是临床治疗BPH的重要方法之一,值得临床推广和应用。

Objective To compare the clinical effect between combined drug therapy of 5α-reductase inhibitors and α1A-adrenergic receptor blocker and did not combine for treatment of benign prostatic hyperplasia（BPH）.Methods 76 patients with BPH were randomly divided into experimental group（38 cases） and control group（38 cases）.Patients in the experimental group received the basic treatment combined drug therapy of 5α-reductase inhibitors the（epristeride） and α1A adrenergic-blocker（doxazosin） and in the control group only received general treatment.The clinical parameters and international prostate symptom score（IPSS）,quality of life（QQL）,the maximal urinary flow rate（Qmax） and prostate volume（PV） were compared three months later.Results Compared with control group,the IPSS,QOL and Qmax and PV were significantly improved（P0.05） combined drug therapy.However,there were no significantly change in PV（P0.05）.The conclusion at the same time taking the 5α-reductase inhibitors and adrenergic α1A-receptor blocker drug therapy is one of theimportant method of clinical treatment of BPH.Conclusion The drug therapy of the 5α-reductase inhibitors and α1A-adrenergic receptor blocker is one of significant methods for treatment of benign prostatic hyperplasia,and worthy of promotion and application.